ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 543

Cytokine Signaling Pathways Inhibited by Different Biologics in Rheumatoid Arthritis Patients

Sergio Duran-Barragan1, Efrain Chavarria-Avila 1, Marisol Esesarte-Rodriguez 1, Rosal Valenzuela-Marrufo 1, Karla Arrona-Ríos 1, Jorge Aguilar-Arreola 1, Oscar Pizano Martínez 1 and Monica Vazquez-del Mercado 1, 1Universidad de Guadalajara, Guadalajara, Jalisco, Mexico

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: DMARDs and cytokines, rheumatoid arthritis, treatment

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Session Title: RA – Treatments Poster I: Novel Treatments

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Different types of cells play pathogenic roles in Rheumatoid Arthritis (RA). The immunogenetics of RA suggests a key role of aberrant pathways of T cell activation in the onset and/or perpetuation of the disease. The differentiation of the naïve CD4 T cell is aimed at differentiating into Th1, Th2 and Th17. These molecules probably play a key role in the local generation of specific autoantibodies participating in the autoimmune cascade. Biological treatments for RA interfere different signaling pathways (CD28/CTLA4 system, TNF-α inhibitor, CD20 B cell depleting, IL-6 inhibition, JAKs inhibitors). There are no reports dealing about the impact of serological expression of cytokine profile in RA patients.

Methods: RA patients treated with DMARDs ( >3 months) (Methotrexate) and/or biological drugs (Abatecept, Certolizumab pegol, Rituximab, Tocilizumab, Tofacitinib and Baricitinib) attending to two rheumatology outpatient clinics were recruited. Blood sample were analyzed by the LEGENDplex Human Inflammation Panel method to perform the profile of cytokines. Disease activity was measured by DAS28-ESR scale, physical functionality with HAQ questionnaire and quality of life of the patient through the EuroQol 5-D questionnaire.

Statistical analysis: Data were presented as numbers, percentage, mean±SD. ANOVA test was performed to compare treatment between groups. P value ≤ 0.05 were considered statistical significant.

Results: Seventy-two RA patients were included, 64 (89%) were female and 19 (26%) smokers. Patients had different comorbidities: 6 (8%) diabetes mellitus, 14 (19%) high blood pressure, 4 (5%) ischemic cardiopathy and 10 (14%) osteoporosis. Ninty-eigth percent were positive for rheumatoid factor and 96% for anti-CCP. Treatment for RA were as follow: Abatacept 11 (15%), Certolizumab nine (13%), Rituximab 11 (15%) Tocilizumab nine (13%), Tofacitinib 10 (14%), Baricitinib 11 (15%), and Methotrexate monotherapy 11 (15%). Cytokine profile according to treatment is presented in Table 1.

Conclusion: Tofacitinib seems to have a better performance inhibiting the cytokine profile in RA patients. More studies and bigger sample are needed to replicate these finding.

Table 1. Cytokine profile according to treatment by ANOVA


Disclosure: S. Duran-Barragan, None; E. Chavarria-Avila, None; M. Esesarte-Rodriguez, None; R. Valenzuela-Marrufo, None; K. Arrona-Ríos, None; J. Aguilar-Arreola, None; O. Pizano Martínez, None; M. Vazquez-del Mercado, None.

To cite this abstract in AMA style:

Duran-Barragan S, Chavarria-Avila E, Esesarte-Rodriguez M, Valenzuela-Marrufo R, Arrona-Ríos K, Aguilar-Arreola J, Pizano Martínez O, Vazquez-del Mercado M. Cytokine Signaling Pathways Inhibited by Different Biologics in Rheumatoid Arthritis Patients [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/cytokine-signaling-pathways-inhibited-by-different-biologics-in-rheumatoid-arthritis-patients/. Accessed May 17, 2022.
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cytokine-signaling-pathways-inhibited-by-different-biologics-in-rheumatoid-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.